NEJM Evidence-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1207962, encodeId=ebdf120e962bf, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：meta分析;医学综合;临床试验 经验分享：这是NEJM旗下的新刊，刚刚出版，不过因为NEJM这个高贵血统，估计会有不少文章投NEJM后建议转投到这里。初步看了一些文章，质量还是相当不错的，未来估计影响因子在10-20分之间，不要因为现在没有IF就不投了，毕竟是名门贵族！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=366, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Fri Apr 01 21:27:28 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226380, encodeId=61371226380ba, content=目前大都是nejm的transfer文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Tue Jun 14 14:04:48 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219999, encodeId=234c12199991f, content=等待, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf9e8165767, createdName=ms3000000443376417, createdTime=Mon May 16 13:44:07 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220400, encodeId=c40b12204001e, content=111, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43958165571, createdName=ms9000000795072041, createdTime=Tue May 17 16:39:28 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240257, encodeId=3971124025ea7, content=收不收meta分析啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=276, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e7a5327063, createdName=148bf3b8m15暂无昵称, createdTime=Mon Aug 22 12:06:29 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233662, encodeId=c05112336621d, content=eee, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220719/78e45345e7a54aa7965f216022201f0f/f7c753494cda4f2f866bc9105db59a65.png, createdBy=155c5510995, createdName=YaliMei, createdTime=Wed Jul 20 17:07:54 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226387, encodeId=d05b122638ee0, content=nejm主编：受限于nejm版面，我们不得不reject了很多重要的paper，为了弥补这一缺憾，nejm evidence诞生了。（肥水不流外人田）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=320, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Tue Jun 14 14:21:42 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215624, encodeId=ab8d121562405, content=偏重的研究方向：Meta分析 经验分享：这个杂志有被SCI收录吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=974f6158809, createdName=ms2000000448711869, createdTime=Fri Apr 29 17:07:50 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184987, encodeId=377f218498e43, content=审稿速度:2.0 经验分享：什么时候有影响因子？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d7d70412, createdName=15014e5643m, createdTime=Wed Jan 31 08:57:19 CST 2024, time=2024-01-31, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2131150, encodeId=192b213115024, content=11, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220127/d05bb6afae5547958d72f7f748779d3a/82871b0a56864780a70e9106d8e05ac0.jpg, createdBy=68215628101, createdName=ms3000000528368992, createdTime=Tue May 09 15:04:56 CST 2023, time=2023-05-09, status=1, ipAttribution=上海)]

2022-04-01 医者仁者

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：meta分析;医学综合;临床试验
经验分享：这是NEJM旗下的新刊，刚刚出版，不过因为NEJM这个高贵血统，估计会有不少文章投NEJM后建议转投到这里。初步看了一些文章，质量还是相当不错的，未来估计影响因子在10-20分之间，不要因为现在没有IF就不投了，毕竟是名门贵族！

366 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1207962, encodeId=ebdf120e962bf, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：meta分析;医学综合;临床试验 经验分享：这是NEJM旗下的新刊，刚刚出版，不过因为NEJM这个高贵血统，估计会有不少文章投NEJM后建议转投到这里。初步看了一些文章，质量还是相当不错的，未来估计影响因子在10-20分之间，不要因为现在没有IF就不投了，毕竟是名门贵族！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=366, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Fri Apr 01 21:27:28 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226380, encodeId=61371226380ba, content=目前大都是nejm的transfer文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Tue Jun 14 14:04:48 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219999, encodeId=234c12199991f, content=等待, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf9e8165767, createdName=ms3000000443376417, createdTime=Mon May 16 13:44:07 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220400, encodeId=c40b12204001e, content=111, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43958165571, createdName=ms9000000795072041, createdTime=Tue May 17 16:39:28 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240257, encodeId=3971124025ea7, content=收不收meta分析啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=276, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e7a5327063, createdName=148bf3b8m15暂无昵称, createdTime=Mon Aug 22 12:06:29 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233662, encodeId=c05112336621d, content=eee, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220719/78e45345e7a54aa7965f216022201f0f/f7c753494cda4f2f866bc9105db59a65.png, createdBy=155c5510995, createdName=YaliMei, createdTime=Wed Jul 20 17:07:54 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226387, encodeId=d05b122638ee0, content=nejm主编：受限于nejm版面，我们不得不reject了很多重要的paper，为了弥补这一缺憾，nejm evidence诞生了。（肥水不流外人田）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=320, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Tue Jun 14 14:21:42 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215624, encodeId=ab8d121562405, content=偏重的研究方向：Meta分析 经验分享：这个杂志有被SCI收录吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=974f6158809, createdName=ms2000000448711869, createdTime=Fri Apr 29 17:07:50 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184987, encodeId=377f218498e43, content=审稿速度:2.0 经验分享：什么时候有影响因子？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d7d70412, createdName=15014e5643m, createdTime=Wed Jan 31 08:57:19 CST 2024, time=2024-01-31, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2131150, encodeId=192b213115024, content=11, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220127/d05bb6afae5547958d72f7f748779d3a/82871b0a56864780a70e9106d8e05ac0.jpg, createdBy=68215628101, createdName=ms3000000528368992, createdTime=Tue May 09 15:04:56 CST 2023, time=2023-05-09, status=1, ipAttribution=上海)]

2022-06-14 osmataku

目前大都是nejm的transfer文章

382 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1207962, encodeId=ebdf120e962bf, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：meta分析;医学综合;临床试验 经验分享：这是NEJM旗下的新刊，刚刚出版，不过因为NEJM这个高贵血统，估计会有不少文章投NEJM后建议转投到这里。初步看了一些文章，质量还是相当不错的，未来估计影响因子在10-20分之间，不要因为现在没有IF就不投了，毕竟是名门贵族！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=366, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Fri Apr 01 21:27:28 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226380, encodeId=61371226380ba, content=目前大都是nejm的transfer文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Tue Jun 14 14:04:48 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219999, encodeId=234c12199991f, content=等待, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf9e8165767, createdName=ms3000000443376417, createdTime=Mon May 16 13:44:07 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220400, encodeId=c40b12204001e, content=111, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43958165571, createdName=ms9000000795072041, createdTime=Tue May 17 16:39:28 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240257, encodeId=3971124025ea7, content=收不收meta分析啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=276, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e7a5327063, createdName=148bf3b8m15暂无昵称, createdTime=Mon Aug 22 12:06:29 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233662, encodeId=c05112336621d, content=eee, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220719/78e45345e7a54aa7965f216022201f0f/f7c753494cda4f2f866bc9105db59a65.png, createdBy=155c5510995, createdName=YaliMei, createdTime=Wed Jul 20 17:07:54 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226387, encodeId=d05b122638ee0, content=nejm主编：受限于nejm版面，我们不得不reject了很多重要的paper，为了弥补这一缺憾，nejm evidence诞生了。（肥水不流外人田）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=320, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Tue Jun 14 14:21:42 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215624, encodeId=ab8d121562405, content=偏重的研究方向：Meta分析 经验分享：这个杂志有被SCI收录吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=974f6158809, createdName=ms2000000448711869, createdTime=Fri Apr 29 17:07:50 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184987, encodeId=377f218498e43, content=审稿速度:2.0 经验分享：什么时候有影响因子？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d7d70412, createdName=15014e5643m, createdTime=Wed Jan 31 08:57:19 CST 2024, time=2024-01-31, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2131150, encodeId=192b213115024, content=11, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220127/d05bb6afae5547958d72f7f748779d3a/82871b0a56864780a70e9106d8e05ac0.jpg, createdBy=68215628101, createdName=ms3000000528368992, createdTime=Tue May 09 15:04:56 CST 2023, time=2023-05-09, status=1, ipAttribution=上海)]

2022-05-16 ms3000000443376417

等待

82 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1207962, encodeId=ebdf120e962bf, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：meta分析;医学综合;临床试验 经验分享：这是NEJM旗下的新刊，刚刚出版，不过因为NEJM这个高贵血统，估计会有不少文章投NEJM后建议转投到这里。初步看了一些文章，质量还是相当不错的，未来估计影响因子在10-20分之间，不要因为现在没有IF就不投了，毕竟是名门贵族！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=366, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Fri Apr 01 21:27:28 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226380, encodeId=61371226380ba, content=目前大都是nejm的transfer文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Tue Jun 14 14:04:48 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219999, encodeId=234c12199991f, content=等待, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf9e8165767, createdName=ms3000000443376417, createdTime=Mon May 16 13:44:07 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220400, encodeId=c40b12204001e, content=111, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43958165571, createdName=ms9000000795072041, createdTime=Tue May 17 16:39:28 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240257, encodeId=3971124025ea7, content=收不收meta分析啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=276, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e7a5327063, createdName=148bf3b8m15暂无昵称, createdTime=Mon Aug 22 12:06:29 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233662, encodeId=c05112336621d, content=eee, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220719/78e45345e7a54aa7965f216022201f0f/f7c753494cda4f2f866bc9105db59a65.png, createdBy=155c5510995, createdName=YaliMei, createdTime=Wed Jul 20 17:07:54 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226387, encodeId=d05b122638ee0, content=nejm主编：受限于nejm版面，我们不得不reject了很多重要的paper，为了弥补这一缺憾，nejm evidence诞生了。（肥水不流外人田）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=320, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Tue Jun 14 14:21:42 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215624, encodeId=ab8d121562405, content=偏重的研究方向：Meta分析 经验分享：这个杂志有被SCI收录吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=974f6158809, createdName=ms2000000448711869, createdTime=Fri Apr 29 17:07:50 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184987, encodeId=377f218498e43, content=审稿速度:2.0 经验分享：什么时候有影响因子？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d7d70412, createdName=15014e5643m, createdTime=Wed Jan 31 08:57:19 CST 2024, time=2024-01-31, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2131150, encodeId=192b213115024, content=11, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220127/d05bb6afae5547958d72f7f748779d3a/82871b0a56864780a70e9106d8e05ac0.jpg, createdBy=68215628101, createdName=ms3000000528368992, createdTime=Tue May 09 15:04:56 CST 2023, time=2023-05-09, status=1, ipAttribution=上海)]

2022-05-17 ms9000000795072041

111

100 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1207962, encodeId=ebdf120e962bf, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：meta分析;医学综合;临床试验 经验分享：这是NEJM旗下的新刊，刚刚出版，不过因为NEJM这个高贵血统，估计会有不少文章投NEJM后建议转投到这里。初步看了一些文章，质量还是相当不错的，未来估计影响因子在10-20分之间，不要因为现在没有IF就不投了，毕竟是名门贵族！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=366, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Fri Apr 01 21:27:28 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226380, encodeId=61371226380ba, content=目前大都是nejm的transfer文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Tue Jun 14 14:04:48 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219999, encodeId=234c12199991f, content=等待, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf9e8165767, createdName=ms3000000443376417, createdTime=Mon May 16 13:44:07 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220400, encodeId=c40b12204001e, content=111, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43958165571, createdName=ms9000000795072041, createdTime=Tue May 17 16:39:28 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240257, encodeId=3971124025ea7, content=收不收meta分析啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=276, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e7a5327063, createdName=148bf3b8m15暂无昵称, createdTime=Mon Aug 22 12:06:29 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233662, encodeId=c05112336621d, content=eee, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220719/78e45345e7a54aa7965f216022201f0f/f7c753494cda4f2f866bc9105db59a65.png, createdBy=155c5510995, createdName=YaliMei, createdTime=Wed Jul 20 17:07:54 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226387, encodeId=d05b122638ee0, content=nejm主编：受限于nejm版面，我们不得不reject了很多重要的paper，为了弥补这一缺憾，nejm evidence诞生了。（肥水不流外人田）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=320, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Tue Jun 14 14:21:42 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215624, encodeId=ab8d121562405, content=偏重的研究方向：Meta分析 经验分享：这个杂志有被SCI收录吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=974f6158809, createdName=ms2000000448711869, createdTime=Fri Apr 29 17:07:50 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184987, encodeId=377f218498e43, content=审稿速度:2.0 经验分享：什么时候有影响因子？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d7d70412, createdName=15014e5643m, createdTime=Wed Jan 31 08:57:19 CST 2024, time=2024-01-31, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2131150, encodeId=192b213115024, content=11, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220127/d05bb6afae5547958d72f7f748779d3a/82871b0a56864780a70e9106d8e05ac0.jpg, createdBy=68215628101, createdName=ms3000000528368992, createdTime=Tue May 09 15:04:56 CST 2023, time=2023-05-09, status=1, ipAttribution=上海)]

2022-08-22 148bf3b8m15暂无昵称

收不收meta分析啊

276 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1207962, encodeId=ebdf120e962bf, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：meta分析;医学综合;临床试验 经验分享：这是NEJM旗下的新刊，刚刚出版，不过因为NEJM这个高贵血统，估计会有不少文章投NEJM后建议转投到这里。初步看了一些文章，质量还是相当不错的，未来估计影响因子在10-20分之间，不要因为现在没有IF就不投了，毕竟是名门贵族！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=366, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Fri Apr 01 21:27:28 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226380, encodeId=61371226380ba, content=目前大都是nejm的transfer文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Tue Jun 14 14:04:48 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219999, encodeId=234c12199991f, content=等待, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf9e8165767, createdName=ms3000000443376417, createdTime=Mon May 16 13:44:07 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220400, encodeId=c40b12204001e, content=111, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43958165571, createdName=ms9000000795072041, createdTime=Tue May 17 16:39:28 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240257, encodeId=3971124025ea7, content=收不收meta分析啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=276, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e7a5327063, createdName=148bf3b8m15暂无昵称, createdTime=Mon Aug 22 12:06:29 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233662, encodeId=c05112336621d, content=eee, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220719/78e45345e7a54aa7965f216022201f0f/f7c753494cda4f2f866bc9105db59a65.png, createdBy=155c5510995, createdName=YaliMei, createdTime=Wed Jul 20 17:07:54 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226387, encodeId=d05b122638ee0, content=nejm主编：受限于nejm版面，我们不得不reject了很多重要的paper，为了弥补这一缺憾，nejm evidence诞生了。（肥水不流外人田）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=320, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Tue Jun 14 14:21:42 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215624, encodeId=ab8d121562405, content=偏重的研究方向：Meta分析 经验分享：这个杂志有被SCI收录吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=974f6158809, createdName=ms2000000448711869, createdTime=Fri Apr 29 17:07:50 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184987, encodeId=377f218498e43, content=审稿速度:2.0 经验分享：什么时候有影响因子？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d7d70412, createdName=15014e5643m, createdTime=Wed Jan 31 08:57:19 CST 2024, time=2024-01-31, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2131150, encodeId=192b213115024, content=11, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220127/d05bb6afae5547958d72f7f748779d3a/82871b0a56864780a70e9106d8e05ac0.jpg, createdBy=68215628101, createdName=ms3000000528368992, createdTime=Tue May 09 15:04:56 CST 2023, time=2023-05-09, status=1, ipAttribution=上海)]

2022-07-20 YaliMei

eee

304 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1207962, encodeId=ebdf120e962bf, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：meta分析;医学综合;临床试验 经验分享：这是NEJM旗下的新刊，刚刚出版，不过因为NEJM这个高贵血统，估计会有不少文章投NEJM后建议转投到这里。初步看了一些文章，质量还是相当不错的，未来估计影响因子在10-20分之间，不要因为现在没有IF就不投了，毕竟是名门贵族！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=366, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Fri Apr 01 21:27:28 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226380, encodeId=61371226380ba, content=目前大都是nejm的transfer文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Tue Jun 14 14:04:48 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219999, encodeId=234c12199991f, content=等待, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf9e8165767, createdName=ms3000000443376417, createdTime=Mon May 16 13:44:07 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220400, encodeId=c40b12204001e, content=111, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43958165571, createdName=ms9000000795072041, createdTime=Tue May 17 16:39:28 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240257, encodeId=3971124025ea7, content=收不收meta分析啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=276, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e7a5327063, createdName=148bf3b8m15暂无昵称, createdTime=Mon Aug 22 12:06:29 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233662, encodeId=c05112336621d, content=eee, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220719/78e45345e7a54aa7965f216022201f0f/f7c753494cda4f2f866bc9105db59a65.png, createdBy=155c5510995, createdName=YaliMei, createdTime=Wed Jul 20 17:07:54 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226387, encodeId=d05b122638ee0, content=nejm主编：受限于nejm版面，我们不得不reject了很多重要的paper，为了弥补这一缺憾，nejm evidence诞生了。（肥水不流外人田）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=320, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Tue Jun 14 14:21:42 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215624, encodeId=ab8d121562405, content=偏重的研究方向：Meta分析 经验分享：这个杂志有被SCI收录吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=974f6158809, createdName=ms2000000448711869, createdTime=Fri Apr 29 17:07:50 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184987, encodeId=377f218498e43, content=审稿速度:2.0 经验分享：什么时候有影响因子？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d7d70412, createdName=15014e5643m, createdTime=Wed Jan 31 08:57:19 CST 2024, time=2024-01-31, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2131150, encodeId=192b213115024, content=11, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220127/d05bb6afae5547958d72f7f748779d3a/82871b0a56864780a70e9106d8e05ac0.jpg, createdBy=68215628101, createdName=ms3000000528368992, createdTime=Tue May 09 15:04:56 CST 2023, time=2023-05-09, status=1, ipAttribution=上海)]

2022-06-14 osmataku

nejm主编：受限于nejm版面，我们不得不reject了很多重要的paper，为了弥补这一缺憾，nejm evidence诞生了。（肥水不流外人田）

320 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1207962, encodeId=ebdf120e962bf, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：meta分析;医学综合;临床试验 经验分享：这是NEJM旗下的新刊，刚刚出版，不过因为NEJM这个高贵血统，估计会有不少文章投NEJM后建议转投到这里。初步看了一些文章，质量还是相当不错的，未来估计影响因子在10-20分之间，不要因为现在没有IF就不投了，毕竟是名门贵族！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=366, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Fri Apr 01 21:27:28 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226380, encodeId=61371226380ba, content=目前大都是nejm的transfer文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Tue Jun 14 14:04:48 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219999, encodeId=234c12199991f, content=等待, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf9e8165767, createdName=ms3000000443376417, createdTime=Mon May 16 13:44:07 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220400, encodeId=c40b12204001e, content=111, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43958165571, createdName=ms9000000795072041, createdTime=Tue May 17 16:39:28 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240257, encodeId=3971124025ea7, content=收不收meta分析啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=276, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e7a5327063, createdName=148bf3b8m15暂无昵称, createdTime=Mon Aug 22 12:06:29 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233662, encodeId=c05112336621d, content=eee, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220719/78e45345e7a54aa7965f216022201f0f/f7c753494cda4f2f866bc9105db59a65.png, createdBy=155c5510995, createdName=YaliMei, createdTime=Wed Jul 20 17:07:54 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226387, encodeId=d05b122638ee0, content=nejm主编：受限于nejm版面，我们不得不reject了很多重要的paper，为了弥补这一缺憾，nejm evidence诞生了。（肥水不流外人田）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=320, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Tue Jun 14 14:21:42 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215624, encodeId=ab8d121562405, content=偏重的研究方向：Meta分析 经验分享：这个杂志有被SCI收录吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=974f6158809, createdName=ms2000000448711869, createdTime=Fri Apr 29 17:07:50 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184987, encodeId=377f218498e43, content=审稿速度:2.0 经验分享：什么时候有影响因子？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d7d70412, createdName=15014e5643m, createdTime=Wed Jan 31 08:57:19 CST 2024, time=2024-01-31, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2131150, encodeId=192b213115024, content=11, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220127/d05bb6afae5547958d72f7f748779d3a/82871b0a56864780a70e9106d8e05ac0.jpg, createdBy=68215628101, createdName=ms3000000528368992, createdTime=Tue May 09 15:04:56 CST 2023, time=2023-05-09, status=1, ipAttribution=上海)]

2022-04-29 ms2000000448711869

偏重的研究方向：Meta分析
经验分享：这个杂志有被SCI收录吗？

104 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1207962, encodeId=ebdf120e962bf, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：meta分析;医学综合;临床试验 经验分享：这是NEJM旗下的新刊，刚刚出版，不过因为NEJM这个高贵血统，估计会有不少文章投NEJM后建议转投到这里。初步看了一些文章，质量还是相当不错的，未来估计影响因子在10-20分之间，不要因为现在没有IF就不投了，毕竟是名门贵族！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=366, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Fri Apr 01 21:27:28 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226380, encodeId=61371226380ba, content=目前大都是nejm的transfer文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Tue Jun 14 14:04:48 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219999, encodeId=234c12199991f, content=等待, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf9e8165767, createdName=ms3000000443376417, createdTime=Mon May 16 13:44:07 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220400, encodeId=c40b12204001e, content=111, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43958165571, createdName=ms9000000795072041, createdTime=Tue May 17 16:39:28 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240257, encodeId=3971124025ea7, content=收不收meta分析啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=276, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e7a5327063, createdName=148bf3b8m15暂无昵称, createdTime=Mon Aug 22 12:06:29 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233662, encodeId=c05112336621d, content=eee, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220719/78e45345e7a54aa7965f216022201f0f/f7c753494cda4f2f866bc9105db59a65.png, createdBy=155c5510995, createdName=YaliMei, createdTime=Wed Jul 20 17:07:54 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226387, encodeId=d05b122638ee0, content=nejm主编：受限于nejm版面，我们不得不reject了很多重要的paper，为了弥补这一缺憾，nejm evidence诞生了。（肥水不流外人田）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=320, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Tue Jun 14 14:21:42 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215624, encodeId=ab8d121562405, content=偏重的研究方向：Meta分析 经验分享：这个杂志有被SCI收录吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=974f6158809, createdName=ms2000000448711869, createdTime=Fri Apr 29 17:07:50 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184987, encodeId=377f218498e43, content=审稿速度:2.0 经验分享：什么时候有影响因子？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d7d70412, createdName=15014e5643m, createdTime=Wed Jan 31 08:57:19 CST 2024, time=2024-01-31, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2131150, encodeId=192b213115024, content=11, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220127/d05bb6afae5547958d72f7f748779d3a/82871b0a56864780a70e9106d8e05ac0.jpg, createdBy=68215628101, createdName=ms3000000528368992, createdTime=Tue May 09 15:04:56 CST 2023, time=2023-05-09, status=1, ipAttribution=上海)]

2024-01-31 15014e5643m 来自重庆

审稿速度:2.0
经验分享：什么时候有影响因子？

25 0

[GetPortalCommentsPageByObjectIdResponse(id=1207962, encodeId=ebdf120e962bf, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：meta分析;医学综合;临床试验 经验分享：这是NEJM旗下的新刊，刚刚出版，不过因为NEJM这个高贵血统，估计会有不少文章投NEJM后建议转投到这里。初步看了一些文章，质量还是相当不错的，未来估计影响因子在10-20分之间，不要因为现在没有IF就不投了，毕竟是名门贵族！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=366, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Fri Apr 01 21:27:28 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226380, encodeId=61371226380ba, content=目前大都是nejm的transfer文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Tue Jun 14 14:04:48 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219999, encodeId=234c12199991f, content=等待, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf9e8165767, createdName=ms3000000443376417, createdTime=Mon May 16 13:44:07 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220400, encodeId=c40b12204001e, content=111, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43958165571, createdName=ms9000000795072041, createdTime=Tue May 17 16:39:28 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240257, encodeId=3971124025ea7, content=收不收meta分析啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=276, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e7a5327063, createdName=148bf3b8m15暂无昵称, createdTime=Mon Aug 22 12:06:29 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233662, encodeId=c05112336621d, content=eee, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220719/78e45345e7a54aa7965f216022201f0f/f7c753494cda4f2f866bc9105db59a65.png, createdBy=155c5510995, createdName=YaliMei, createdTime=Wed Jul 20 17:07:54 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226387, encodeId=d05b122638ee0, content=nejm主编：受限于nejm版面，我们不得不reject了很多重要的paper，为了弥补这一缺憾，nejm evidence诞生了。（肥水不流外人田）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=320, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Tue Jun 14 14:21:42 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215624, encodeId=ab8d121562405, content=偏重的研究方向：Meta分析 经验分享：这个杂志有被SCI收录吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=974f6158809, createdName=ms2000000448711869, createdTime=Fri Apr 29 17:07:50 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184987, encodeId=377f218498e43, content=审稿速度:2.0 经验分享：什么时候有影响因子？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d7d70412, createdName=15014e5643m, createdTime=Wed Jan 31 08:57:19 CST 2024, time=2024-01-31, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2131150, encodeId=192b213115024, content=11, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220127/d05bb6afae5547958d72f7f748779d3a/82871b0a56864780a70e9106d8e05ac0.jpg, createdBy=68215628101, createdName=ms3000000528368992, createdTime=Tue May 09 15:04:56 CST 2023, time=2023-05-09, status=1, ipAttribution=上海)]

2023-05-09 ms3000000528368992 来自上海

11

64 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务